Forest Stock Hits New 52-Week High (FRX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Forest Laboratories (NYSE: FRX) hit a new 52-week high Friday as it is currently trading at $40.61, above its previous 52-week high of $40.49 with 109,771 shares traded as of 10:11 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Forest has a market cap of $10.65 billion and is part of the health care sector and drugs industry. Shares are up 14.2% year to date as of the close of trading on Thursday.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Forest as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Forest Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Cramer: There Are Some Bargains Out There

Cramer: There Are Some Bargains Out There

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Why Endo International Can Deliver Solid Rewards With Minimal Risk

3 Stocks Driving The Health Care Sector Higher